Kadmon Reveals A Bit Of Its Hand To Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
Kadmon CEO Sam Waksal - the former CEO of ImClone - laid out the startup's ambitious pipeline during the Jeffries Healthcare Conference.
You may also be interested in...
Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle
Vertex Pharmaceuticals' Incivek (telaprevir) has cleared FDA with labeling advantages that should enable it to win a majority of patients in the battle against Merck's competing protease inhibitor for hepatitis C, Victrelis (boceprevir).
Back In Biotech, Waksal's Kadmon Emerges From Stealth Mode To Focus on Hep C
Deal with Valeant brings development and commercialization rights to ribavirin analog that could have better safety profile for anemia.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.